Lykos Therapeutics Revenue and Competitors

Location

$100M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Lykos Therapeutics's estimated annual revenue is currently $20.6M per year.(i)
  • Lykos Therapeutics's estimated revenue per employee is $155,000
  • Lykos Therapeutics's total funding is $100M.

Employee Data

  • Lykos Therapeutics has 133 Employees.(i)
  • Lykos Therapeutics grew their employee count by -36% last year.

Lykos Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Interim General Counsel and Chief Compliance OfficerReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief StaffReveal Email/Phone
6
Chief Commercial Officer (CCO)Reveal Email/Phone
7
Chief Government Affairs and AdvocacyReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
Head Global QualityReveal Email/Phone
10
VP, CMCReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Lykos Therapeutics?

At Lykos Therapeutics, our mission is to transform mental healthcare. We’re applying decades of evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a Public Benefit Company, we are focused on delivering positive impact on our people, communities and society. To learn more, visit us at www.lykospbc.com.

keywords:N/A

$100M

Total Funding

133

Number of Employees

$20.6M

Revenue (est)

-36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.3M13316%N/A
#2
$33.4M1331%$18.5M
#3
$19.4M13452%N/A
#4
$13.7M134-7%N/A
#5
$28.1M1340%N/A